Quadrupole, time-of-flight, orbital trap: what each class can and cannot see
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
Salomé Adeyemi
Page 11 of 13 of this archive, newest first.
Archive — page 11
243 piecesMaximum tolerated is not maximum approved
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
The effect profile, predicted from an expression map
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Australia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Target dose, effective dose, and the distance between them
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Sweden guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dual, triple, co-formulated: a taxonomy the coverage keeps collapsing
Head-to-head data exists for some of these comparisons and not for others. This piece says which.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
GIP was a failed target for thirty years. Then it was not.
A dual agonist is one molecule with two receptor activities. A co-formulation is two molecules in one pen. The coverage treats them as synonyms.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new South Korea guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the trials adjudicated, and how
The features that should prompt urgent assessment, stated once and plainly.
What STEP 4 and SURMOUNT-4 actually established
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.